Furthermore, the DESTINY-CRC01 trial, a multicenter, open-label, phase II study evaluating patients with HER2-expressing metastatic colorectal cancer, reported that patients receiving T-DXd 6.4 mg/kg every 3 weeks achieved an objective response rate of 45.3%, a disease control rate of 83.0%, a median progression-free survival of 6.9 months, and a median overall survival of 15.5 months, suggesting robust and durable antitumor activity in patients with HER2-positive metastatic colorectal cancer (25). This evidence concerns the gene ERBB2 and metastatic colorectal cancer.